|

Validation of a microRNA-based Fecal (miRFec) Test for Colorectal Cancer Screening, Surveillance and Diagnosis

RECRUITINGN/ASponsored by Fundacion Clinic per a la Recerca Biomédica
Actively Recruiting
PhaseN/A
SponsorFundacion Clinic per a la Recerca Biomédica
Started2022-03-23
Est. completion2027-01-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted

Summary

The present study aims to compare effectiveness and cost-effectiveness of the miRFec test with respect to fecal immunochemical test (FIT) for the detection of advanced colorectal neoplasm among individuals participating in colorectal cancer (CRC) screening, surveillance and diagnosis.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Male or female aged 50 to 75 (average-risk) referred to colonoscopy-based CRC screening.
* Male or female aged 30 to 80 with family history of CRC (moderate-risk) referred to colonoscopy-based CRC screening.
* Male and female aged 18 or older with personal history of colorectal polyps referred to colonoscopy surveillance.
* Male and female aged 18 or older with personal history of CRC referred to colonoscopy surveillance.
* Male and female aged 18 or older with colorectal symptoms referred to diagnostic colonoscopy.

Exclusion Criteria:

* Lack of informed consent to participate
* Personal history of Lynch syndrome
* Personal history of adenomatous or hamartomatous polyposis
* Personal history of serrated polyposis syndrome
* Personal history of inflammatory bowel disease
* Personal history of total colectomy for any reason
* Family history of Lynch syndrome
* Family history of adenomatous or hamartomatous polyposis
* Family history of serrated polyposis syndrome

Conditions2

CancerColorectal Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.